HIPEC for Peritoneal Mesothelioma: Who Qualifies and What to Expect in 2026

What Are HIPEC and Cytoreductive Surgery, and Why Are They Used Together?

Peritoneal mesothelioma is a rare cancer of the lining of the abdominal cavity. Untreated, the median survival is roughly 5 to 12 months. Systemic chemotherapy alone extends median survival to 11 to 13 months. The combination of cytoreductive surgery and HIPEC has changed that trajectory more than any other intervention: at high-volume centers, modern series report median overall survival of 38 to 53 months for all comers and 5-year survival above 80 percent in optimally selected patients. The U.S. National Cancer Institute and the 2025 PSM Consortium consensus guideline both recognize CRS-HIPEC as the standard of care for resectable disease.

The two procedures are performed in a single operation:

• Cytoreductive surgery (CRS) — the surgeon physically removes every visible tumor deposit from the peritoneal cavity. Depending on the disease distribution, this may involve stripping the peritoneal lining off the diaphragm, pelvis, or abdominal wall, removing the omentum, and resecting any involved bowel, spleen, gallbladder, uterus, ovaries, or other organs.
• Hyperthermic intraperitoneal chemotherapy (HIPEC) — once the visible disease is removed, the abdomen is filled with chemotherapy heated to 41 to 43 degrees Celsius. The heated solution is circulated by perfusion pumps for 60 to 90 minutes, killing microscopic disease that surgery cannot see.

Who Qualifies for CRS-HIPEC?

The 2025 PSM Consortium consensus guideline standardized eligibility around four criteria. Each one matters; missing any single criterion does not automatically rule out surgery, but the combination defines the candidate pool that has historically achieved long-term survival.

1. Histology — confirmed peritoneal mesothelioma, preferably epithelioid

Epithelioid disease (about 70 to 80 percent of cases) responds best to CRS-HIPEC. Biphasic disease — a mix of epithelioid and sarcomatoid features — is considered case by case, with surgery favored when the epithelioid component dominates. Sarcomatoid mesothelioma is generally not a surgical candidate. Diagnosis must be confirmed on tissue biopsy with immunohistochemistry; cytology of ascites alone is not enough.

2. Disease distribution — Peritoneal Cancer Index (PCI) of 20 or below

The PCI score is calculated by dividing the abdomen into 13 regions and scoring each region 0 to 3 based on the largest tumor nodule present. Total scores range from 0 (no visible disease) to 39 (extensive bulky disease in every region). Patients with PCI 0 to 20 have the highest likelihood of complete cytoreduction (CC-0) and the longest survival. PCI 21 to 30 is borderline and is sometimes managed with neoadjuvant chemotherapy or laparoscopic HIPEC to downstage to surgical eligibility. PCI above 30 is generally considered unresectable.

3. Performance status and organ function

CRS-HIPEC is a long, physiologically demanding operation. Candidates need ECOG performance status of 0 to 2 (fully active, or restricted only in strenuous activity). Cardiac evaluation typically includes echocardiogram and stress testing. Pulmonary function tests, renal function (estimated GFR above 60), and hepatic function are also assessed. Patients with significant heart failure, dialysis-dependent kidney disease, severe COPD, or recent major cardiac events are usually not candidates.

4. No extra-abdominal disease

Peritoneal mesothelioma that has spread outside the abdomen — to the pleural cavity, mediastinal lymph nodes, liver parenchyma (versus liver capsule, which is often resectable), or distant sites — is not amenable to surgery as the primary treatment. PET-CT and chest imaging are used to rule out extra-abdominal spread before any operation is offered.

"The single most useful conversation a peritoneal mesothelioma patient can have in their first month after diagnosis is a referral discussion with a high-volume CRS-HIPEC surgeon. Even if surgery turns out not to be the right answer, the eligibility evaluation itself reframes the entire treatment plan around what is actually possible — and at expert centers, more is possible than most patients are first told."

— David Foster, Executive Director of Client Services and Host of the MESO Podcast, Danziger & De Llano

What Should You Expect Before Surgery?

The pre-operative evaluation typically takes 2 to 4 weeks and includes:

1. Imaging and staging. CT of the chest, abdomen, and pelvis with intravenous contrast. PET-CT to rule out extra-abdominal spread. Some centers add MRI of the abdomen and pelvis for better peritoneal-disease mapping.
2. Diagnostic laparoscopy. A small-incision look inside the abdomen to confirm the PCI score and assess feasibility of complete cytoreduction. Laparoscopy is more accurate than imaging alone for PCI estimation.
3. Multidisciplinary tumor board review. Surgical oncology, medical oncology, pathology, radiology, and palliative care meet to align on the recommended treatment plan.
4. Pre-operative optimization. Nutritional assessment and supplementation if needed (most patients have lost weight). Pulmonary rehab if smoking history. Smoking cessation. Iron repletion if anemic. Cardiac and pulmonary clearance.
5. Genetic counseling. Germline testing for BAP1 mutations is increasingly recommended, both for treatment implications and for at-risk family members. The 2025 ASCO mesothelioma guideline endorses universal germline testing.
6. Psychosocial planning. CRS-HIPEC recovery involves at least 2 weeks in the hospital and 2 to 3 months out of work. Most centers connect patients with social workers, financial counselors, and peer-support resources before surgery.

What Happens on the Day of Surgery?

The operative day typically follows this rhythm:

• Pre-op (1 to 2 hours): arrival, anesthesia consultation, IV access, epidural catheter placement for post-op pain control, antibiotics.
• Cytoreduction (4 to 8 hours): the surgeon opens the abdomen, performs a thorough exploration, and systematically removes every visible tumor deposit. This may include peritonectomy of the right diaphragm, left diaphragm, anterior abdominal wall, pelvis, and porta hepatis; omentectomy; and resection of bowel segments, the spleen, gallbladder, or other organs as needed.
• HIPEC perfusion (60 to 90 minutes): inflow and outflow catheters are placed, the abdomen is filled with chemotherapy heated to 41 to 43 degrees Celsius, and the solution is circulated. The 2025 PSM Consortium preferred regimen is cisplatin plus doxorubicin.
• Reconstruction (1 to 3 hours): any anastomoses (rejoining of bowel) are completed, drains are placed, and the abdomen is closed.
• Recovery (immediate): the patient is transferred to a surgical intensive care unit on a ventilator, with planned extubation within 12 to 24 hours.

What Does Recovery Look Like in the First 90 Days?

ICU and ward stay (days 1 to 14)

Most patients spend 1 to 4 days in the ICU and another 7 to 14 days on a surgical ward. Common early issues include:

• Ileus. Bowel function returns slowly after extensive intra-abdominal surgery. Most patients are not eating solid food for 5 to 10 days and rely on IV nutrition or gradual liquid advancement.
• Pain. Epidural analgesia is the standard for the first 3 to 5 days, transitioned to oral medication afterward.
• Electrolyte and fluid management. The HIPEC perfusion plus extensive surgery cause large fluid shifts; patients often need careful daily lab monitoring.
• Mobility. Walking starts on day 1 or 2 with assistance and progresses each day.

Home recovery (days 14 to 90)

By discharge, most patients can walk short distances and tolerate a soft diet. Over the next 2 to 3 months, expect:

• Weight loss of 10 to 20 pounds during the first month, gradually reversing as oral intake improves.
• Fatigue lasting 6 to 12 weeks, often longer for older patients or those with major resections.
• Surveillance imaging at 6 to 12 weeks to confirm there is no early recurrence.
• Return to baseline activities by week 12 for most patients; full strength and stamina recovery often takes 6 to 12 months.
• Adjuvant systemic therapy decisions made at the 6-to-12-week mark, depending on histology, completeness of cytoreduction, and tumor biology.

Major complications occur in roughly 30 to 50 percent of CRS-HIPEC patients, most often anastomotic leaks, abscesses, bleeding, or pulmonary issues. Operative mortality at expert centers is 0 to 2.1 percent — comparable to other major abdominal cancer surgery.

What If You Are Not a Candidate for CRS-HIPEC?

Roughly half of patients evaluated for CRS-HIPEC ultimately do not undergo it — usually because of high PCI, sarcomatoid histology, comorbidities, or extra-abdominal disease. Non-surgical options include:

• Systemic chemotherapy. Cisplatin plus pemetrexed remains the standard first-line systemic regimen, with median overall survival of 11 to 13 months. Carboplatin can substitute for patients who cannot tolerate cisplatin.
• Immunotherapy. Nivolumab plus ipilimumab is increasingly used in unresectable peritoneal disease following its approval in pleural mesothelioma (CheckMate 743). Recent case series and a 2025 French real-world cohort show meaningful disease control in selected patients.
• Neoadjuvant downstaging. Patients with borderline-resectable disease (PCI 21 to 30) are sometimes converted to surgical candidates with 3 to 6 cycles of systemic chemotherapy or laparoscopic HIPEC.
• Clinical trials. Active programs in 2026 include mesothelin-targeted CAR-T at Memorial Sloan Kettering, the National Cancer Institute Surgical Branch, antibody-drug conjugates, and combination immunotherapy regimens. The full list of recruiting trials is searchable at ClinicalTrials.gov.
• Palliative procedures. Tunneled peritoneal catheters for symptom control of malignant ascites, palliative chemotherapy, and hospice integration when appropriate.

How Do You Find a High-Volume CRS-HIPEC Center?

Outcomes track strongly with center volume. The U.S. high-volume CRS-HIPEC centers most frequently published in peritoneal mesothelioma include the Washington Cancer Institute (Sugarbaker Oncology Associates), MD Anderson Cancer Center, Memorial Sloan Kettering, Mayo Clinic, Cleveland Clinic, the University of Pittsburgh, the National Cancer Institute Surgical Branch, and Roswell Park Comprehensive Cancer Center. The Peritoneal Surface Malignancy Consortium and the American Society of Peritoneal Surface Malignancies maintain referral resources.

What to ask before choosing a center:

• How many CRS-HIPEC operations does this center perform each year? (Aim for 25 or more.)
• How many CRS-HIPEC procedures does the lead surgeon perform individually each year? (Aim for 10 to 15 or more.)
• What percentage of patients achieve a complete cytoreduction (CC-0)?
• What is this center's 30-day mortality and major morbidity rate?
• Are tumor board reviews and multidisciplinary care standard?
• What is the institution's ability to enroll on relevant clinical trials?

What Are Your Legal and Financial Options If Asbestos Exposure Is Part of Your History?

Approximately 30 to 50 percent of peritoneal mesothelioma cases are linked to asbestos. The exposure is often occupational — shipyard, insulation, construction, automotive — but secondary household exposure (washing a worker's contaminated clothing) and consumer-product exposure are also recognized. The same compensation routes that exist for pleural mesothelioma apply to peritoneal disease:

• Asbestos trust fund claims. Multiple bankrupt asbestos manufacturers funded compensation trusts (Johns-Manville, Owens Corning, Babcock & Wilcox, and dozens more). A documented diagnosis plus exposure history typically supports claims with every implicated trust.
• Civil litigation against solvent defendants. Manufacturers still in business may be liable for exposure to their products.
• VA benefits. Veterans with documented in-service asbestos exposure can apply for VA disability compensation through the Department of Veterans Affairs (VA asbestos exposure benefits).
• Statute of limitations. Most states allow 2 to 4 years from the date of mesothelioma diagnosis to file. The clock generally starts at diagnosis, not at the date of exposure, because of the disease's long latency.

For a deeper look at compensation pathways, see the WikiMesothelioma trust fund overview and our coverage of average asbestos trust fund payouts in 2026. Background on the disease itself is at pleural vs. peritoneal mesothelioma and on the WikiMesothelioma peritoneal page. Additional treatment-center research is summarized at Mesothelioma Lawyer Center.

How Danziger & De Llano Helps Peritoneal Mesothelioma Patients

Our firm has represented mesothelioma patients and their families nationwide for more than 30 years. Peritoneal mesothelioma cases require the same exposure reconstruction as pleural cases, and the same trust fund and litigation pathways apply. We work with industrial hygienists, treating physicians, and our internal client services team to build cases that account for both the medical reality of CRS-HIPEC and the financial realities of out-of-state treatment, lost income, caregiver burden, and household impact. There is no fee unless we recover compensation for your family.

If you or a family member was diagnosed with peritoneal mesothelioma, take our free case evaluation quiz, learn more at dandell.com, or call (855) 699-5441 for a confidential consultation. To find a treatment center, see our peritoneal mesothelioma treatment guide and our mesothelioma lawyers near you directory.